Table 3 Characteristics of PROQOL participants
Variables | ALL | Not on Rx | NNRTI | PI | p-value |
|---|---|---|---|---|---|
| Â | N = 102 | N = 15 | N = 46 | N = 41 | Â |
Female | 15 (14.7%) | 4 (26.7%) | 7 (15.2%) | 4 (9.8%) | p=0.3 |
Age | 46 (37–53.8) | 41 (32.5-49.5) | 48 (37–56.5) | 45 (40–53) | p=0.4 |
Transmission | Â | Â | Â | Â | p=0.08 |
Heterosexual/other | 42 (41.2%) | 10 (66.7%) | 21 (45.7%) | 11 (26.8%) | Â |
IDU | 6 (5.9%) | 0 (0%) | 3 (6.5%) | 3 (7.3%) | Â |
MSM | 54 (52.9%) | 5 (33.3%) | 22 (47.8%) | 27 (65.9%) | Â |
Married | 34 (33.3%) | 5 (33.3%) | 17 (37%) | 12 (29.3%) | p=0.7 |
Caucasian | 80 (78.4%) | 9 (60%) | 37 (80.4%) | 34 (82.9%) | p=0.2 |
Living alone | 40 (39.2%) | 8 (53.3%) | 16 (34.8%) | 16 (39%) | p=0.5 |
Post-secondary | 37 (36.3%) | 6 (40%) | 17 (37%) | 14 (34.1%) | p=0.9 |
Unemployed/sickness benefits | 18 (17.6%) | 2 (13.3%) | 3 (6.5%) | 13 (31.7%) | p=0.007 |
Smoker ≥ 2 cigarettes/day | 41 (40.2%) | 4 (26.7%) | 19 (41.3%) | 18 (43.9%) | p=0.0002 |
Alcohol ≥ 2 glasses/day | 15 (14.7%) | 1 (6.7%) | 7 (15.2%) | 7 (17.1%) | p=0.5 |
Diagnosed < 2 years | 16 (15.7%) | 8 (53.3%) | 6 (13%) | 2 (4.9%) | p=0.7 |
Time since diagnosis (years) | 7.3 (2.9-15.6) | 1.5 (0.8-3.8) | 6.8 (3.2-11.9) | 13.2 (6.2-18.9) | p<0.0001 |
Body mass index | 24.3 (22–28) | 23.6 (22–28) | 25.4 (23–28) | 23.9 (22–27) | p=0.5 |
CD4 T cells | 530 (376–733) | 546 (512–695) | 591 (386–853) | 455 (323–638) | p=0.1 |
Undetectable VL | 77 (75.5%) | 2 (13.3%) | 43 (93.5%) | 32 (78%) | p<0.0001 |
Time on ART (years) | 4.2 (0.8-11.8) | - | 4.4 (2.1-9.9) | 10.7 (3.2-13.6) | p<0.0001 |
On non-ART medication | 38 (37.3%) | 3 (20%) | 15 (32.6%) | 20 (48.8%) | p=0.1 |
ART pill burden (tablets/day) | 3 (2–5) | - | 2.5 (2–3) | 4 (3–5) | p<0.0001 |
Non-adherent to ART | 18 (17.6%) | - | 7 (15.2%) | 11 (26.8%) | p=0.2 |
Depressive | 26 (25.5%) | 3 (20%) | 8 (17.4%) | 15 (36.6%) | p=0.1 |
Other comorbidity | 56 (54.9%) | 8 (53.3%) | 20 (43.5%) | 28 (68.3%) | p=0.07 |
Sexual dysfunction | 25 (24.5%) | 4 (26.7%) | 9 (19.6%) | 12 (29.3%) | p=0.5 |
Number symptoms (total) | 5 (2–10) | 4 (1–10.5) | 5 (1–8) | 8 (5–12) | p=0.01 |